Know Cancer

forgot password

An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.

Phase 2
18 Years
Open (Enrolling)
Stomach Neoplasms, Gastroesophageal Junction Neoplasms

Thank you

Trial Information

An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.

Inclusion Criteria:

- Competent to comprehend, sign, and date an IEC-approved informed consent form,
written informed consent.

- Of either gender and aged 18 years or more.

- Diagnosed with histologically confirmed adenocarcinoma of the stomach or the
gastroesophageal junction of Type I/II/III according to the classification of Siewert
et al, 1996.

- Stage uT/3 or 4 N0/+ and M0 disease evaluated by endoscopic ultrasound, spiral
computed tomography of the chest, abdomen and pelvis and by laparoscopy in uT3/T4

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- Leucocyte count > 3,000/mm3.

- Platelet count ≥100,000/mm3.

- Haemoglobin ≥10 g/dl.

- Serum creatinine ≤ 1.5x of upper limit of normal (ULN).

- Creatinine clearance > 60 ml/kg/min measured either by 24-h urine sampling or
calculated by using the Cockcroft-Gault formula .

- Aspartate aminotransferase (AST) ≤3 x ULN.

- Alanine aminotransferase (ALT) ≤3 x ULN.

- Bilirubin ≤ 1.5 x ULN.

- Magnesium ≥ lower limit of normal.

- Calcium ≥ lower limit of normal.

- Subject is deemed a good candidate for surgery.

Exclusion Criteria:

- Any metastatic disease.

- Other malignant tumours less than five years old. Exceptions include basocellular
carcinoma, in situ cancer of the cervix of the uterus, or any curatively-treated
other malignancies without evidence of disease for more than five years.

- Significant ascites or pleural effusion.

- Prior anti-EGFr antibody therapy (e.g. cetuximab) or treatment with small molecule
EGFr tyrosine kinase inhibitors (e.g. erlotinib).

- Prior chemotherapy, radiotherapy or antibody therapy for gastric cancer or cancer of
the gastro-oesophageal junction.

- Concomitant therapy with sorivudine or analogue compounds.

- Known previous or ongoing abuse of narcotic drug, other medication or alcohol.

- Significant cardiovascular disease including New York Heart Association (NYHA) grade
II or greater congestive heart failure, peripheral arterial occlusive disease stage
II or greater, symptomatic coronary heart disease, insufficiently treated arterial
hypertension, unstable angina or myocardial infarction within 12 months before
initiating study treatment or a history of ventricular arrhythmia.

- History or evidence upon physical examination of CNS disease unless adequately
treated, seizure not controlled with standard medical therapy, or history of stroke.

- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
pneumonitis or pulmonary fibrosis on baseline chest CT scan.

- Pre-existing polyneuropathy grade >1 according to the National Cancer Institute's
Common Terminology Criteria for Adverse Events (NCI CTCAE), except for loss of tendon
reflex as the only symptom.

- Treatment for systemic infection within 14 days before initiating study treatment.

- Active inflammatory bowel disease, serious gastric ulceration or other bowel disease
causing chronic diarrhoea (defined as > 4 loose stools per day).

- Suspected or known dihydropyrimidine dehydrogenase deficiency (DPD).

- Thrombosis or severe bleeding within six months prior to entry into the study (except
for bleeding of the tumour before its surgical resection), evidence of bleeding
diathesis or coagulopathy, or current or recent (within 10 days prior to initiation
of study treatment) use of full-dose oral or parenteral anticoagulants for
therapeutic purposes.

- History of any medical condition that may increase the risks associated with study
participation or may interfere with the interpretation of the study results.

- Known positive test for human immunodeficiency virus infection, hepatitis C virus or
chronic active hepatitis B infection.

- Known allergy to the investigational product, to any of its excipients, to monoclonal
antibodies, or to any of the components of the chemotherapy regimen.

- Any co-morbid disease that would increase risk of toxicity.

- Any kind of disorder that compromises the ability of the subject to give written
informed consent and/or comply with the study procedures.

- Any investigational agent or participation in another clinical trial within 30 days
prior to randomisation.

- Must not have had a major surgical procedure within 28 days of randomisation.

- Subject who is pregnant or breast feeding.

- Woman or man of childbearing potential not consenting to use adequate contraceptive
precautions (intrauterine contraceptive device, contraceptive implants, injectables
(hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual
abstinence or vasectomised partner) during the course of the study and for six months
after the last study drug administration for women and men. Post-menopausal women
must have been amenorrheic for at least 12 months to be considered of
non-child-bearing potential.

- Subject unwilling or unable to comply with study requirements.

- Hearing impairment

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Frequency of pT3/T4 categories after surgery

Outcome Time Frame:

after 9 weeks treatment

Safety Issue:


Principal Investigator

Hansjochen Wilke, Prof. Dr. med.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Klinken Essen-Mitte Evang. Huyssens-Stiftung


Germany: Paul-Ehrlich-Institut

Study ID:




Start Date:

October 2010

Completion Date:

September 2014

Related Keywords:

  • Stomach Neoplasms
  • Gastroesophageal Junction Neoplasms
  • Stomach Neoplasms
  • Gastroesophageal Junction Neoplasms
  • gastric cancer
  • cancer of the gastroesophageal junction
  • Neoplasms
  • Stomach Neoplasms